Alloy Therapeutics, Inc.’s Post

CMTRF is pleased to announce that we have invested over $500,000 in a program led by 82VS, the venture studio of Alloy Therapeutics, Inc. to discover and develop novel Antibody Oligonucleotide Conjugate therapeutics for CMT. Oligonucleotide therapeutics offer promise for treating genetic disorders but have faced challenges as potential drugs for CMT due to limited delivery to the peripheral nerves and affected cell types. Transferrin receptor (TfR1) antibodies have recently been shown to enhance oligonucleotide delivery to muscle, brain and peripheral nerves. This project by 82VS aims to combine Alloy Therapeutics' novel TfR1 antibodies with oligonucleotides to improve delivery and efficacy in CMT-relevant tissues. If successful, this approach could enable treatments for all types of CMT. Read more here: https://lnkd.in/gbA9tD7p

Providence Therapeutics: Advancing Lipid Nanoparticle Technology At Providence Therapeutics, we understand the critical role that lipid nanoparticles (LNPs) play in the development and delivery of mRNA-based therapeutics. With the global LNP demand expected to grow significantly in the future, our focus on this technology is strategically aligned with industry trends. Why Lipids Matter: - Extensive Library: We have developed a library of over 200 rationally designed ionizable lipids, intended for applications including cancer vaccines, infectious diseases, and gene delivery. - Manufacturability: Our ionizable lipids are first screened to ensure efficient manufacture into a stable lipid nanoparticle. - Proven Efficacy: Our lipid technology has been rigorously tested, demonstrating its effectiveness in enhancing the delivery of mRNA, both in vitro and in vivo, across multiple therapeutic areas. - Strategic Growth: As we continue to advance our mRNA platform, lipid technology remains central to our innovation strategy, opening new avenues for collaboration and enhancing the efficacy and safety of our therapeutic offerings. We believe our progress in lipid technology not only strengthens our current pipeline but also positions us as a leader in the rapidly growing field of mRNA therapeutics. If you would like to know more about our lipids or our programs in different therapeutic areas, send us a message at BD@providencetherapeutics.com

[Clinical Trials] 09/30 Windtree Therapeutics, Inc. reports phase 2b clinical results of istaroxime, showing improved systolic blood pressure in heart failure patients same day : ( ↓ NASDAQ: WINT | -3.89% ) 09/27 BridgeBio Pharma's Post hoc analysis of phase 3 Study Reveals Reduction in Mortality and Hospitalizations with Acoramidis Treatment [Deals] 09/30 Prime Medicine, Inc. and Bristol Myers Squibb Ink Deal to Develop Next-Gen T-cell Therapies, Prime to Receive $110M Plus Potential $3.5B in Milestones same day : ( ↑ NYSE: BMY | +0.88% ) ( ↑ NASDAQ: PRME | +34.4% ) 09/30 Nanoscope Therapeutics Inc. secures CatCh Technology license from Max Planck Innovation to advance gene therapy for vision restoration 09/30 Celaid Therapeutics receives $19M grant from AMED for development of pediatric hematopoietic stem cell therapy 09/30 Alphamab Oncology Subsidiary Licenses Anti-HER2 Bispecific ADC to JMT-Bio for 3.08B RMB with Double-Digit Royalties on Net Sales 09/30 Genentech and Regor Pharmaceuticals Ink $850M Deal for Next-Generation CDK Inhibitors Development in Breast Cancer Treatment 09/30 Valerio Therapeutics acquires Emglev Therapeutics, forms Valour Bio to develop single domain antibodies [Venture Capital] 09/30 Aktis Oncology Raises $175 Million in Series B Financing to Advance Nectin-4-Targeted Radiopharmaceuticals [Regulatory] 09/30 FDA Approves Formycon AG and Fresenius Kabi's Biosimilar FYB202 for Treatment of Crohn’s Disease and Other Conditions View the full newsletter contents for free via the link in the comments.

#Antibody #Drug #Conjugates Market Size, Share & Trends Analysis Report By Component (Monoclonal Antibodies, Cytotoxic Agent, and Others), By Technology (Cleavable, Non-cleavable, Linker Technology, Payload Technology), By Target (Antibody-Protein Toxin Conjugates, Antibody-Chelated Radionuclide Conjugates, Antibody-Small-Molecule Drug Conjugates, Antibody-Enzyme Conjugates), By Application (Lymphoma, Ovarian Cancer, Lung Cancer, Breast Cancer, Brain Tumor, and Others), By End User (Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast Till 2031. 📚 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲 𝘀𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁:👇 https://lnkd.in/dvK-d9Qz The Antibody Drug Conjugates (ADC) market is evolving rapidly, driven by advancements in cancer therapies and the increasing need for targeted treatments. Here are the key points: Market Growth: The ADC market is expanding due to the increasing prevalence of cancer and the demand for more effective, less toxic treatments. ADCs combine monoclonal antibodies with cytotoxic drugs to selectively target cancer cells, improving treatment efficacy while minimizing damage to healthy tissues. Therapeutic Applications: ADCs are primarily used in oncology, particularly for treating solid tumors and hematologic cancers. They are gaining traction in the treatment of breast cancer, lymphoma, and leukemia. AbbVie Abzena ADC Therapeutics Adcendo Agensys Corporation. Ambrx Angiex Inc. Antikor Biopharma Ltd Araris Biotech AG Astellas Pharma AstraZeneca Bayer Hellas AG BioPharmaSpec Bio-Thera Solutions BiVictriX Therapeutics plc BroadPharm Celldex Therapeutics Concortis Biosystems Corp  Daiichi Sankyo US  Elucida Oncology, Inc. GBI Bio Genentech Genmab Gilead Sciences, Glycotope GmbH GSK GTP Bioways Heidelberg Pharma AG Iksuda Therapeutics ImmunoGen, Inc. Immunomedics. Mersana Therapeutics MILLENNIUM PHARMACEUTICALS, INC. Myrio Tx Mythic Therapeutics, Inc. NJ Bio, Inc. Novartis Orum Therapeutics Oxford BioTherapeutics

Mixed Lymphocyte reaction (MLR) assay : The MLR assay serves as a critical tool in biopharma, providing insights into the complex interactions of immune cells. By assessing cellular proliferation and cytokine secretion, MLR aids in evaluating the immunomodulatory effects of potential therapeutics. Its customizable nature allows biopharma companies to tailor experiments, accelerating the development of novel immunomodulatory drugs. BioRadius is a premier CRO specializing in supporting preclinical in vitro immuno-oncology endeavors. Our diverse assay portfolio encompasses mixed lymphocyte reaction assay (MLR), Antibody-dependent cellular cytotoxicity (ADCC), custom T-cell activation bioassays, MLR, and Immune mediated tumour killing assays. These assays are tailored to your unique requirements, offering comprehensive insights to navigate early-stage drug development confidently. Collaborate with BioRadius to unlock the potential of your immuno-oncology innovations and expedite the path to groundbreaking cancer therapies. #MLRassay #biosimilars #Tcellassays #immunooncology #invitro cell based assays #ADCC #biopharmaceuticals

Are mRNA Cell Therapies the future? We have recently seen an increased interest in RNA developers looking to apply their technologies towards cell therapies, and needing to gather comprehensive intelligence for this landscape. Whilst mRNA vaccines are a far more advanced application (see below graph) we are starting to see some interesting clinical data for mRNA enhanced cell therapies with activity across both oncology & autoimmune diseases. Interesting mRNA cell therapies in the pipeline include: ·      Myeloid Therapeutics in vivo CAR macrophage program targeting TROP-2 which is delivered via LNP ·      Cartesian Therapeutics ex vivo autologous cell therapies for autoimmune conditions including SLE & Myasthenia gravis ·     Eterna Therapeutics / Factor Bioscience Inc. iMSCs derived from mRNA-engineered B2M0KO iPSCs ·     Capstan Therapeutics CD5 & CD19 CAR-T programs delivered via LNP For developers working on cross over modalities, the need to understand both landscapes at a deeper level becomes more complicated, as you look to benchmark a novel modality against the wider cell therapy landscape (6,900+ drugs) & understand delivery trends from the mRNA landscape (1,300+ drugs). Beacon’s modality approach has both angles covered across our RNA & Cell Therapy modules, which are built in a way to answer complex questions for both modalities within seconds, cut down large landscapes into niche segments and find all companies, deals, preclinical & clinical data tagged and curated in one place. More info here: Beacon RNA: https://lnkd.in/efBCyQ3y Beacon Cell Therapy: https://lnkd.in/e3TGhaMf #mRNA #celltherapy #invivoCAR #LNP

Glad to see our B-hPD-1/hPD-L1 mice (https://lnkd.in/ejuMX3DA) supporting the discovery of novel immune-checkpoint drugs! #mousemodel #preclinicalresesarch #therapeutics #immunotherapy  #immunooncology #drugdiscovery #pharmacology #immunecheckpoint #tumormodel

𝟏𝟖 𝐒𝐰𝐢𝐬𝐬 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐨 𝐩𝐮𝐭 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐫𝐚𝐝𝐚𝐫 📡 #Biotech companies in #Switzerland are heavily invested in developing new #cancer treatments and #immunotherapies, with #pharma giants #Novartis and #Roche playing the role of powerhouses in this space. Switzerland is also a hub for gene and #celltherapy development and contributes to #research on therapies targeting the aging process and age-related diseases, exemplified by Rejuveron Life Sciences’ impressive portfolio in the field. Jules ADAM, Labiotech.eu presents 18 biotech companies based in Switzerland worth keeping an eye on. Alentis Therapeutics Araris Biotech AG CDR-Life Inc. CUTISS AG Endogena Therapeutics, Inc. Engimmune Therapeutics FoRx Therapeutics GlycoEra AG HAYA Therapeutics ImmunOs Therapeutics AG iOnctura MUVON Therapeutics AG Noema Pharma NewBiologix Nouscom STALICLA Synendos Therapeutics AG TOLREMO therapeutics Read on: https://lnkd.in/dnb2WuGu

We will present at the PBSS-San Francisco Bay Symposium: Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays The abstract of this symposium: The era of one-size-fits-all pharmaceuticals is fading. Today, the drug development landscape brims with groundbreaking modalities - from gene and cell therapies to mRNA and antibody-drug conjugates (ADCs) armed with radiotherapy. This transformative journey demands equally disruptive tools to streamline and accelerate research. Join us at this symposium as we explore the frontier of technology propelling the discovery of next-generation therapeutics. This symposium will showcase a diverse arsenal of tools designed to empower every stage of drug development. Topics include single-cell analysis, AI-based protein design, cancer organoids for drug screening, multiplex assays sans detecting agents, and sensitive NGS/multiomic biomarker profiling assays revealing previously hidden disease complexity. These advancements reflect the continuous pursuit of innovation, accelerating the quest for more effective, targeted, and ultimately, transformative therapeutic solutions. Registration and Agenda link: https://lnkd.in/gY8gy-jQ